Interactions of spironolactone with (+)-[3H]-isradipine and (-)-[3H]-desmethoxyverapamil binding sites in vascular smooth muscle.
Spironolactone partially inhibited the specific binding of (+)-[3H]-isradipine and (-)-[3H]-desmethoxyverapamil to vascular smooth muscle membranes. It is suggested that spironolactone interacts at a binding site of the calcium channel complex and allosterically modulates ligand binding at receptor sites in the channel.
Mironneau
J
J
Laboratoire de Physiologie Cellulaire et Pharmacologie Moléculaire, INSERM Jeune Formation 88-13, Université de Bordeaux, France.
Sayet
I
I
Rakotoarisoa
L
L
Dacquet
C
C
Mironneau
C
C
D000818:Animals; D001665:Binding Sites; D002121:Calcium Channel Blockers / Q000378:metabolism*; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D006736:Horses; D066298:In Vitro Techniques; D017275:Isradipine; D008024:Ligands; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism*; D011169:Portal Vein / Q000378:metabolism; D011374:Progesterone / Q000494:pharmacology; D011725:Pyridines / Q000378:metabolism*; D013148:Spironolactone / Q000494:pharmacology*; D014700:Verapamil / Q000031:analogs & derivatives* / Q000378:metabolism
D002121:Calcium Channel Blockers; D008024:Ligands; D011725:Pyridines; D013148:Spironolactone; D011374:Progesterone; C043184:4-desmethoxyverapamil; D014700:Verapamil; D017275:Isradipine